[ad_1]
Riverwater Companions, an funding administration firm, launched its “Micro Alternatives Technique” This fall 2025 investor letter. A replica of the letter might be downloaded right here. Each This fall and the total yr 2025 have been difficult for the technique, which struggled to match the benchmark efficiency in This fall and FY2025. The underweight publicity in speculative areas of the market led to the underperformance within the second half of the yr. Low-quality shares with poor fundamentals outperformed the market within the yr. The technique’s emphasis on high-quality shares lagged behind the broader market tendencies. Heading to 2026, the Technique focuses on micro-cap firms with broader gross sales and development trajectories and believes that the low-quality inventory market rallies can be short-lived. As well as, you may verify the fund’s high 5 holdings to find out its finest picks for 2025.
Within the fourth-quarter 2025 investor letter, Riverwater Companions Micro Alternatives Technique highlighted IRADIMED CORPORATION (NASDAQ:IRMD) as its high efficiency contributor. Headquartered in Orlando, Florida, IRADIMED CORPORATION (NASDAQ:IRMD) is a magnetic resonance imaging (MRI) appropriate medical gadget producer. The one-month return for IRADIMED CORPORATION (NASDAQ:IRMD) was 5.01%, and its shares gained 72.38% over the past 52 weeks. On December 15, 2025, IRADIMED CORPORATION (NASDAQ:IRMD) inventory closed at $102.00 per share, with a market capitalization of $1.244 billion.
Riverwater Companions Micro Alternatives Technique said the next relating to IRADIMED CORPORATION (NASDAQ:IRMD) in its fourth quarter 2025 investor letter:
“IRADIMED CORPORATION (NASDAQ:IRMD) was our high contributor for each the quarter and the total yr. The MRI-compatible medical gadget firm rallied almost 38% within the fourth quarter and gained roughly 80% for the yr.
IRADIMED CORPORATION (NASDAQ:IRMD) is just not on our checklist of 30 Most In style Shares Amongst Hedge Funds. As per our database, 14 hedge fund portfolios held IRADIMED CORPORATION (NASDAQ:IRMD) on the finish of the third quarter, which was 13 within the earlier quarter. In Q3 2025, IRADIMED CORPORATION (NASDAQ:IRMD) reported file income of $21.2 million, marking a rise of 16% from Q3 2024. Whereas we acknowledge the potential of IRADIMED CORPORATION (NASDAQ:IRMD) as an funding, we consider sure AI shares supply higher upside potential and carry much less draw back threat. For those who’re on the lookout for a particularly undervalued AI inventory that additionally stands to learn considerably from Trump-era tariffs and the onshoring pattern, see our free report on the finest short-term AI inventory.
[ad_2]
